Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,079)

Items 201–300 of 1,079

1. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
   Gary J. Kelloff, John M. Hoffman, Bruce Evan Johnson, Howard I. Scher, Barry Alan Siegel, Edward Y. Cheng, Bruce D. Cheson, Joyce O’Shaughnessy, Kathryn Z. Guyton, David A. Mankoff et al. · 2005 · Clinical Cancer Research
2. Feedback regulation of EGFR signalling: decision making by early and delayed loops
   Roi Avraham, Yosef Yarden · 2011 · Nature Reviews Molecular Cell Biology
3. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR
   Khalid N I Al-Nedawi, Brian Meehan, Robert S. Kerbel, ANTHONY C. ALLISON, Janusz W. Rak · 2009 · Proceedings of the National Academy of Sciences
4. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
   Gao, Sizhi Paul, Mark, Kevin G., Leslie, Kenneth, Pao, William, Motoi, Noriko, Gerald, William L., Travis, William D., Bornmann, William, Veach, Darren, Clarkson, Bayard et al. · 2007 · Journal of Clinical Investigation
5. Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations
   Margaret C. Thompson, Christine E. Fuller, Twala L. Hogg, James Dalton, David Finkelstein, Ching C. Lau, Murali Chintagumpala, Adekunle M. Adesina, David M. Ashley, Stewart J. Kellie et al. · 2006 · Journal of Clinical Oncology
6. Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
   Sequist, Lecia V., Soria, Jean-Charles, Goldman, Jonathan W., Wakelee, Heather A., Gadgeel, Shirish M., Varga, Andrea, Papadimitrakopoulou, Vassiliki, Solomon, Benjamin J., Oxnard, Geoffrey R., Dziadziuszko, Rafal et al. · 2015 · New England Journal of Medicine
7. Recurrent gene fusions in prostate cancer
   Chandan Kumar‐Sinha, Scott A. Tomlins, Arul M. Chinnaiyan · 2008 · Nature reviews. Cancer
8. Tyrosine phosphorylation: thirty years and counting
   Tony R. Hunter · 2009 · Current Opinion in Cell Biology
9. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
   James Andrew McCubrey, Linda S. Steelman, Steven L. Abrams, John Tayu Lee, Fumin Chang, Fred E. Bertrand, Patrick M. Navolanic, David M. Terrian, Richard A. Franklin, Antonio B. D’Assoro et al. · 2006 · Advances in Enzyme Regulation
10. Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Zhu, Chang-Qi, da Cunha Santos, Gilda, Ding, Keyue, Sakurada, Akira, Cutz, Jean-Claude, Liu, Ni, Zhang, Tong, Marrano, Paula, Whitehead, Marlo, Squire, Jeremy A. et al. · 2008 · Journal of Clinical Oncology
11. Mechanisms and insights into drug resistance in cancer
    Hiba Ahmad Zahreddine, Katherine L. B. Borden · 2013 · Frontiers in Pharmacology
12. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
    Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee et al. · 2021 · Journal of Clinical Oncology
13. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
    Hisayuki Shigematsu, Adi F. Gazdar · 2005 · International Journal of Cancer
14. EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
    Yamashita, Taro, Forgues, Marshonna, Wang, Wei, Kim, Jin Woo, Ye, Qinghai, Jia, Huliang, Budhu, Anuradha, Zanetti, Krista A., Chen, Yidong, Qin, Lun-Xiu et al. · 2008 · Cancer Research
15. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
    Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad Shahrokh Esfahani, Aaron M. Newman, Henry J. Haringsma, David Matthew Kurtz, Henning Stehr, Florian Scherer, Chris Karlovich et al. · 2016 · Nature Communications
16. Cancer genomics: from discovery science to personalized medicine
    Lynda Chin, Jannik N. Andersen, P. Andrew Futreal · 2011 · Nature Medicine
17. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    Yano, Seiji, Wang, Wei, Li, Qi, Matsumoto, Kunio, Sakurama, Haruko, Nakamura, Takahiro, Ogino, Hirokazu, Kakiuchi, Soji, Hanibuchi, Masaki, Nishioka, Yasuhiko et al. · 2008 · Cancer Research
18. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith William Pratz, Gabriel Pallares, Qi Chao et al. · 2009 · Blood
19. Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers
    Dogan, Snjezana, Shen, Ronglai, Ang, Daphne C., Johnson, Melissa L., D'Angelo, Sandra P., Paik, Paul K., Brzostowski, Edyta B., Riely, Gregory J., Kris, Mark G., Zakowski, Maureen F. et al. · 2012 · Clinical Cancer Research
20. Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions
    William J. Pao, Vincent A. Miller · 2005 · Journal of Clinical Oncology
21. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
    Pîlar Eroles, Ana Bosch, José Alejandro Pérez Fidalgo, Ana M. Lluch · 2011 · Cancer Treatment Reviews
22. Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
    Lecia Van Dam Sequist, Daphne W. Bell, Thomas James Lynch, Daniel A. Haber · 2007 · Journal of Clinical Oncology
23. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
    Peter T. Harrison, Simon Vyse, Paul H. Huang · 2019 · Seminars in Cancer Biology
24. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
    Hata, Aaron N., Engelman, Jeffrey A., Faber, Anthony C. · 2015 · Cancer Discovery
25. Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene
    Jesse S. Boehm, Jean J. Zhao, Jun Yao, So Young Kim, Ron Firestein, Ian F. Dunn, Sarah K. Sjostrom, Levi A. Garraway, Stanislawa Weremowicz, Andrea L. Richardson et al. · 2007 · Cell
26. c-Src and cooperating partners in human cancer
    Ishizawar, Rumey, Parsons, Sarah J. · 2004 · Cancer Cell
27. V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
    Christine A. Pratilas, Barry S. Taylor, Qing Ye, Agnes J. Viale, Chris Sander, David B. Solit, Neal X. Rosen · 2009 · Proceedings of the National Academy of Sciences
28. Genomics and Drug Response
    Liewei Wang, Howard L. McLeod, Richard M. Weinshilboum · 2011 · New England Journal of Medicine
29. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
    Yasuda, Hiroyuki, Kobayashi, Susumu, Costa, Daniel B · 2012 · The Lancet Oncology
30. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
    Mitsudomi, Tetsuya, Yatabe, Yasushi · 2007 · Cancer Science
31. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
    Jianming Zhang, Francisco Adrián, Wolfgang Jahnke, Sandra W. Cowan‐Jacob, Allen G. Li, Roxana E. Iacob, Taebo Sim, John T. Powers, Christine Dierks, Fangxian Sun et al. · 2010 · Nature
32. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
    Daphne W. Bell, Thomas James Lynch, Sara M. Haserlat, Patricia L. Harris, Ross A. Okimoto, Brian W. Brannigan, Dennis C. Sgroi, Beth Muir, Markus J. Riemenschneider, Renee Bailey Iacona et al. · 2005 · Journal of Clinical Oncology
33. KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
    Erminia Massarelli, Marileila Varella‐Garcia, Ximing Tang, Ana C. Xavier, Natalie C. Ozburn, Diane D. Liu, Benjamin Nebiyou Bekele, Roy S. Herbst, Ignacio Ivan Wistuba · 2007 · Clinical Cancer Research
34. Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
    Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh, Kimihide Yoshida, Toyoaki Hida, Masahiro Tsuboi, Hirohito Tada, Hiroyuki Kuwano, Tetsuya Mitsudomi · 2006 · Clinical Cancer Research
35. Molecular and histological correlations in liver cancer
    Julien Caldéraro, Marianne Ziol, Valérie Paradis, Jessica Zucman‐Rossi · 2019 · Journal of Hepatology
36. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
    Uribe, Mary Luz, Marrocco, Ilaria, Yarden, Yosef · 2021 · Cancers
37. Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
    Jackman, David M., Yeap, Beow Y., Sequist, Lecia V., Lindeman, Neal, Holmes, Alison J., Joshi, Victoria A., Bell, Daphne W., Huberman, Mark S., Halmos, Balazs, Rabin, Michael S. et al. · 2006 · Clinical Cancer Research
38. The transcriptional landscape and mutational profile of lung adenocarcinoma
    Jeong‐Sun Seo, Young Seok Ju, Won‐Chul Lee, Jong-Yeon Shin, Jake June-Koo Lee, Thomas Bleazard, Junho Lee, Yoo Jin Jung, Jung Oh Kim, Jung-Young Shin et al. · 2012 · Genome Research
39. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
    Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J. et al. · 2018 · Journal of Thoracic Oncology
40. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
    Arcila, Maria E., Oxnard, Geoffrey R., Nafa, Khedoudja, Riely, Gregory J., Solomon, Stephen B., Zakowski, Maureen F., Kris, Mark G., Pao, William, Miller, Vincent A., Ladanyi, Marc · 2011 · Clinical Cancer Research
41. Frequency and Distinctive Spectrum of <i>KRAS</i> Mutations in Never Smokers with Lung Adenocarcinoma
    Riely, Gregory J., Kris, Mark G., Rosenbaum, Daniel, Marks, Jenifer, Li, Allan, Chitale, Dhananjay A., Nafa, Khedoudja, Riedel, Elyn R., Hsu, Meier, Pao, William et al. · 2008 · Clinical Cancer Research
42. Overcoming therapy resistance in EGFR-mutant lung cancer
    Passaro, Antonio, Jänne, Pasi A., Mok, Tony, Peters, Solange · 2021 · Nature Cancer
43. Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer
    Patrick C. Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, Maria Tretiakova, Vidya Nallasura, Edward A. Fox, Mark Hansen, Erik M. SCHAEFER, Katsuhiko Naoki, Alan S. Lader et al. · 2005 · Cancer Research
44. ErbB receptors: from oncogenes to targeted cancer therapies
    Hongtao Zhang, Alan Berezov, Qiang Wang, Geng Zhang, Jeffrey A. Drebin, Ramachandran Murali, Mark I. Greene · 2007 · Journal of Clinical Investigation
45. Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
    Martin J. van den Bent, Alba Ariela Brandes, R. Rampling, Mathilde C.M. Kouwenhoven, Johan M. Kros, Antoine F. Carpentier, Paul M. Clément, Marc Frénay, Mario Campone, Jean‐François Baurain et al. · 2009 · Journal of Clinical Oncology
46. Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
    Fred R. Hirsch, Marileila Varella‐Garcia, Jason McCoy, Howard West, Ana Carolina Xavier, Paul H. Gumerlock, Paul A. Bunn, Wilbur A. Franklin, John J. Crowley, David R. Gandara · 2005 · Journal of Clinical Oncology
47. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
    Yasuda, Hiroyuki, Park, Eunyoung, Yun, Cai-Hong, Sng, Natasha J., Lucena-Araujo, Antonio R., Yeo, Wee-Lee, Huberman, Mark S., Cohen, David W., Nakayama, Sohei, Ishioka, Kota et al. · 2013 · Science Translational Medicine
48. Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
    Christine H. Chung, Kim Ely, Loris McGavran, Marileila Varella‐Garcia, Joel S. Parker, Natalie Bejba Parker, Carolyn Jarrett, Jesse Carter, Barbara A. Murphy, James L. Netterville et al. · 2006 · Journal of Clinical Oncology
49. Emerging insights into the molecular and cellular basis of glioblastoma
    Gavin P. Dunn, Mikael L. Rinne, Jill Wykosky, Giannicola Genovese, Steven N. Quayle, Ian F. Dunn, Pankaj Kumar Agarwalla, Milan G. Chheda, Benito Campos, Alan Wang et al. · 2012 · Genes & Development
50. The emerging role of cell-free DNA as a molecular marker for cancer management
    Bronkhorst, Abel Jacobus, Ungerer, Vida, Holdenrieder, Stefan · 2019 · Biomolecular Detection and Quantification
51. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
    Ng, King Pan, Hillmer, Axel M, Chuah, Charles T H, Juan, Wen Chun, Ko, Tun Kiat, Teo, Audrey S M, Ariyaratne, Pramila N, Takahashi, Naoto, Sawada, Kenichi, Fei, Yao et al. · 2012 · Nature Medicine
52. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
    Tetsuya Mitsudomi, Yasushi Yatabe · 2009 · FEBS Journal
53. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
    Inoue, A., Kobayashi, K., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I. et al. · 2013 · Annals of Oncology
54. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
    Lauren A. Byers, Jing Wang, Monique B. Nilsson, Junya Fujimoto, Pierre Saintigny, John S. Yordy, Uma P. Giri, Michael Peyton, You Hong Fan, Lixia Diao et al. · 2012 · Cancer Discovery
55. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
    Todd A. Carter, Lisa M. Wodicka, Neil P. Shah, Anne Marie Velasco, Miles A. Fabian, Daniel K. Treiber, Zdravko V. Milanov, Corey E. Atteridge, William Biggs, Philip T. Edeen et al. · 2005 · Proceedings of the National Academy of Sciences
56. Development of TGF-β signalling inhibitors for cancer therapy
    Jonathan M. Yingling, Kerry L. Blanchard, J. Scott Sawyer · 2004 · Nature Reviews Drug Discovery
57. Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
    Jesper Bøje Andersen, Bart Spee, Boris R. A. Blechacz, Itzhak Avital, Mina Komuta, Andrew P. Barbour, Elizabeth A. Conner, Matthew C. Gillen, Tania Roskams, Lewis Rowland Roberts et al. · 2011 · Gastroenterology
58. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan
    Shiu-Feng Kathy Huang, Hui-Ping Liu, Ling-Hui Li, Yuan-Chieh Ku, Yu-Ning Fu, Hsien‐Yu Tsai, Ya-Ting Chen, Yung‐Feng Lin, Wen-Cheng Chang, Han-Pin Kuo et al. · 2004 · Clinical Cancer Research
59. RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
    Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang et al. · 2012 · Journal of Clinical Oncology
60. Highly parallel identification of essential genes in cancer cells
    Biao Luo, Hiu Wing Cheung, Aravind Subramanian, Tanaz Sharifnia, Michael Okamoto, Xiaoping Yang, Greg Hinkle, Jesse S. Boehm, Rameen Beroukhim, Barbara A. Weir et al. · 2008 · Proceedings of the National Academy of Sciences
61. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
    Hui‐Wen Lo, Sheng-Chieh Hsu, Mohamed Ali‐Seyed, Mehmet Gündüz, Weiya Xia, Yongkun Wei, Geoffrey A. Bartholomeusz, Jin Yuan Shih, Mien‐Chie Hung · 2005 · Cancer Cell
62. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
    Apostolia Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald Steven Falchook, Siqing Fu, Sarina Anne Piha-Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra et al. · 2012 · Clinical Cancer Research
63. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
    Yewale, Chetan, Baradia, Dipesh, Vhora, Imran, Patil, Sushilkumar, Misra, Ambikanandan · 2013 · Biomaterials
64. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
    Li, Qing, Geng, Shan, Luo, Hao, Wang, Wei, Mo, Ya-Qi, Luo, Qing, Wang, Lu, Song, Guan-Bin, Sheng, Jian-Peng, Xu, Bo · 2024 · Signal Transduction and Targeted Therapy
65. Receptor tyrosine kinases: mechanisms of activation and signaling
    Stevan R. Hubbard, W. Todd Miller · 2007 · Current Opinion in Cell Biology
66. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Daphne W. Bell, Ira Gore, Ross A. Okimoto, Nadia Godin-Heymann, Raffaella Sordella, Roseann Mulloy, Sreenath V. Sharma, Brian W. Brannigan, Gayatry Mohapatra, Jeff Settleman et al. · 2005 · Nature Genetics
67. EGFR-Mediated Beclin 1 Phosphorylation in Autophagy Suppression, Tumor Progression, and Tumor Chemoresistance
    Yongjie Wei, Zhongju Zou, Nils Becker, Matthew Anderson, Rhea Sumpter, Guanghua Xiao, Lisa N. Kinch, Prasad R. K. Koduru, Christhunesa Soundararajan Christudass, Robert W. Veltri et al. · 2013 · Cell
68. Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
    Roy S. Herbst, David H. Johnson, Eric D. Mininberg, David Paul Carbone, Ted Henderson, Edward S. Kim, George Blumenschein, Jack J. Lee, Diane D. Liu, Mylene T. Truong et al. · 2005 · Journal of Clinical Oncology
69. Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer
    David Paul Kelsen, Katryn A. Winter, Leonard L. Gunderson, Joanne E. Mortimer, Norman C. Estes, Daniel G. Haller, Jaffer A. Ajani, Walter Kocha, Bruce D. Minsky, Jack A. Roth et al. · 2007 · Journal of Clinical Oncology
70. Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
    Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford, Robert James Mayer, Philip Jordan Gold, Philip J. Stella, Barry C. Mirtsching, Allen Lee Cohn, Andrew William Pippas, Nozar Azarnia et al. · 2006 · Journal of Clinical Oncology
71. Roles for Growth Factors in Cancer Progression
    Esther Witsch, Michael Sela, Yosef Yarden · 2010 · Physiology
72. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Juliann Chmielecki, Jasmine Foo, Geoffrey R. Oxnard, Katherine E. Hutchinson, Kadoaki Ohashi, Romel Somwar, Lu Wang, Katherine R. Amato, Maria E. Arcila, Martin L. Sos et al. · 2011 · Science Translational Medicine
73. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
    Marta Guix, Anthony C. Faber, Shizhen Emily Wang, Maria Graciela Olivares, Youngchul Song, Sherman Qu, Cammie Rinehart, Brenda Seidel, Douglas Yee, Carlos L. Arteaga et al. · 2008 · Journal of Clinical Investigation
74. Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
    Bentires-Alj, Mohamed, Paez, J. Guillermo, David, Frank S., Keilhack, Heike, Halmos, Balazs, Naoki, Katsuhiko, Maris, John M., Richardson, Andrea, Bardelli, Alberto, Sugarbaker, David J. et al. · 2004 · Cancer Research
75. Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
    Tianhong Li, Hsing‐Jien Kung, Philip C. Mack, David R. Gandara · 2013 · Journal of Clinical Oncology
76. Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors
    Jie-Lou Liao · 2007 · Journal of Medicinal Chemistry
77. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Alissa Jamie Cooper, Lecia Van Dam Sequist, Jessica J. Lin · 2022 · Nature Reviews Clinical Oncology
78. Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines
    Samir E. Witta, Robert M. Gemmill, Fred R. Hirsch, Christopher D. Coldren, Karla Hedman, Larisa Ravdel, Barbara A. Helfrich, Rafał Dziadziuszko, Daniel C. F. Chan, Michio Sugita et al. · 2006 · Cancer Research
79. A mouse model for EML4-ALK -positive lung cancer
    Manabu Soda, Shuji Takada, Kengo Takeuchi, Young Lim Choi, Munehiro Enomoto, Toshihide Ueno, Hidenori Haruta, Toru Hamada, Yoshihiro Yamashita, Yuichi Ishikawa et al. · 2008 · Proceedings of the National Academy of Sciences
80. Malignant melanoma: genetics and therapeutics in the genomic era
    Lynda Chin, Levi A. Garraway, David E. Fisher · 2006 · Genes & Development
81. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
    Inoue, Akira, Suzuki, Takuji, Fukuhara, Tatsuro, Maemondo, Makoto, Kimura, Yuichiro, Morikawa, Naoto, Watanabe, Hiroshi, Saijo, Yasuo, Nukiwa, Toshihiro · 2006 · Journal of Clinical Oncology
82. A Genomics-Based Classification of Human Lung Tumors
    Roman Kurt Thomas, Reinhard Buettner, Wolf, Jürgen · 2013 · Science Translational Medicine
83. Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
    Clara O. Montagut, Sreenath V. Sharma, Toshi Shioda, Ultan McDermott, Matthew J. Ulman, Lindsey E. Ulkus, Dora C. Dias-Santagata, Hannah Stubbs, Diana Wing Lee, Anurag Singh et al. · 2008 · Cancer Research
84. Mutation of the PIK3CA oncogene in human cancers
    Karakas, B, Bachman, K E, Park, B H · 2006 · British Journal of Cancer
85. Signaling networks assembled by oncogenic EGFR and c-Met
    Ailan Guo, Judit Villén, Jon M. Kornhauser, Kimberly A. Lee, Matthew P. Stokes, Klarisa Rikova, Anthony P. Possemato, Julie Nardone, Gregory Innocenti, Randall K. Wetzel et al. · 2008 · Proceedings of the National Academy of Sciences
86. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
    Kentaro Inamura · 2017 · Frontiers in Oncology
87. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
    Inoue, Akira, Kobayashi, Kunihiko, Usui, Kazuhiro, Maemondo, Makoto, Okinaga, Shoji, Mikami, Iwao, Ando, Masahiro, Yamazaki, Koichi, Saijo, Yasuo, Gemma, Akihiko et al. · 2009 · Journal of Clinical Oncology
88. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
    Bhang, Hyo-eun C, Ruddy, David A, Krishnamurthy Radhakrishna, Viveksagar, Caushi, Justina X, Zhao, Rui, Hims, Matthew M, Singh, Angad P, Kao, Iris, Rakiec, Daniel, Shaw, Pamela et al. · 2015 · Nature Medicine
89. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
    Kristy J. Gotink, Henk M.W. Verheul · 2009 · Angiogenesis
90. Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp
    Yoshiaki Nagai, Hitoshi Miyazawa, Huqun, Tomoaki Tanaka, Kiyoshi Udagawa, Motoyasu Kato, Shunichiro Fukuyama, Akemi Yokote, Kunihiko Kobayashi, Minoru Kanazawa et al. · 2005 · Cancer Research
91. Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
    Chee Khoon Lee, Chris S. B. Brown, Richard J. Gralla, Vera Hirsh, Sumitra Thongprasert, Chun‐Ming Tsai, Eng Huat Tan, Jcm Ho, D. Chu, Adel Zaatar et al. · 2013 · JNCI Journal of the National Cancer Institute
92. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
    Seike, Masahiro, Goto, Akiteru, Okano, Tetsuya, Bowman, Elise D., Schetter, Aaron J., Horikawa, Izumi, Mathe, Ewy A., Jen, Jin, Yang, Ping, Sugimura, Haruhiko et al. · 2009 · Proceedings of the National Academy of Sciences
93. Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
    Su, Kang-Yi, Chen, Hsuan-Yu, Li, Ker-Chau, Kuo, Min-Liang, Yang, James Chih-Hsin, Chan, Wing-Kai, Ho, Bing-Ching, Chang, Gee-Chen, Shih, Jin-Yuan, Yu, Sung-Liang et al. · 2012 · Journal of Clinical Oncology
94. Cellular Heterogeneity and Molecular Evolution in Cancer
    Vanessa Almendro, Andriy Marusyk, Kornélia Polyák · 2012 · Annual Review of Pathology Mechanisms of Disease
95. BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
    Daniel Botelho Costa, Balázs Halmos, Amit Kumar, Susan Schumer, Mark S. Huberman, Titus J. Boggon, Daniel Geoffrey Tenen, Susumu S. Kobayashi · 2007 · PLoS Medicine
96. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
    Robert Jr. Roskoski · 2018 · Pharmacological Research
97. Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
    Yauch, Robert L., Januario, Thomas, Eberhard, David A., Cavet, Guy, Zhu, Wenjing, Fu, Ling, Pham, Thinh Q., Soriano, Robert, Stinson, Jeremy, Seshagiri, Somasekar et al. · 2005 · Clinical Cancer Research
98. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
    Jeffrey A. Engelman, Pasi Antero Janne, Craig H. Mermel, Joseph Pearlberg, Toru Mukohara, Christina Fleet, Karen M. Cichowski, Bruce Evan Johnson, Lewis C. Cantley · 2005 · Proceedings of the National Academy of Sciences
99. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
    Maria Clemence Schwaederle, Melissa M. Zhao, J. Jack Lee, Alexander M.M. Eggermont, Richard L. Schilsky, John M. Mendelsohn, Vladimir Lazar, Razelle Kurzrock · 2015 · Journal of Clinical Oncology
100. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
     Douillard, Jean-Yves, Shepherd, Frances A., Hirsh, Vera, Mok, Tony, Socinski, Mark A., Gervais, Radj, Liao, Mei-Lin, Bischoff, Helge, Reck, Martin, Sellers, Mark V. et al. · 2010 · Journal of Clinical Oncology